摘要
宫颈癌是全球女性癌症相关死亡的第四大原因。对于复发或转移性宫颈癌,5年生存率仅有17%,这促使临床医生探索新的治疗方案。程序性死亡-1(programmed death-1,PD-1)/程序性死亡配体-1(programmed death ligand-1,PD-L1)抑制剂作为一种免疫治疗手段,在复发或转移性宫颈癌中已表现出一定的优势,但临床数据质量有待进一步提高。研究表明抗血管生成类药物、放化疗的应用可协同PD-1/PD-L1抑制剂的抗癌活性。回顾性梳理总结PD-1/PD-L1抑制剂用于宫颈癌的理论基础及应用现状、联合其他治疗模式的临床试验,以期改善晚期宫颈癌患者的生存预后,讨论并发的免疫相关不良反应和疗效评估指标,以便更好地管理不良反应、指导临床用药。
Cervical cancer is the fourth leading cause of cancer-related deaths in women worldwide.The 5-year survival rate is only 17%for recurrent or metastatic cervical cancer,which impels clinicians to explore new treatment strategies.As an immunotherapy,PD-1/PD-L1 inhibitors have shown certain advantages in recurrent or metastatic cervical cancer,but the quality of clinical data needs to be further improved.Observations have shown the significant synergy of anti-angiogenesis agents,radiotherapy and chemotherapy with PD-1/PD-L1 inhibitors.For the purpose of the improved prognosis of patients with advanced cervical cancer,the team provides an overview of the theoretical basis and application status of PD-1/PD-L1 inhibitors in cervical cancer,as well as several clinical trials in combination with other treatment modes.The team also discusses the subsequent immune-related adverse events and the biomarkers for the evaluation of immunotherapy,so as to better manage adverse reactions and guide clinical medication.
作者
韩品
温静
刘雨晨
孙怡
王元培
任芳(审校)
HAN Pin;WEN Jing;LIU Yu-chen;SUN Yi;WANG Yuan-pei;REN Fang(Department of Gynecology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《国际妇产科学杂志》
CAS
2022年第4期393-397,共5页
Journal of International Obstetrics and Gynecology
基金
国家自然科学基金青年科学基金(81903114)
河南省高等学校重点科研项目计划(20B320041)。
关键词
程序性细胞死亡受体1
宫颈肿瘤
肿瘤复发
局部
肿瘤转移
肿瘤治疗方案
程序性死亡配体-1
Programmed cell death 1 receptor
Uterine cervical neoplasms
Neoplasm recurrence,local
Neoplasm metastasis
Antineoplastic protocols
Programmed death ligand-1
